Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Kartika Kimia
Devon, George Patrick
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Education

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Molecular Docking and ADMET Analysis of Flavonoid Compounds from Bajakah Tampala Stem (Spatholobus littoralis Hassk.) Targeting VEGFR-2 and c-MET Ismail, Dzava Prawinsyah Fairus; Shafa, Nafis; Pendy, Violent Irene; Devon, George Patrick; Yun, Yenny Febriani
Jurnal Kartika Kimia Vol 8 No 2 (2025): Jurnal Kartika Kimia (In Progress)
Publisher : Department of Chemistry, Faculty of Sciences and Informatics, University of Jenderal Achmad Yani

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26874/jkk.v8i2.982

Abstract

Cancer is a condition marked by abnormal and uncontrolled cell growth, with VEGFR-2 and c-MET receptors contributing to tumor angiogenesis, metastasis, and resistance to therapy. Bajakah tampala stem (Spatholobus littoralis Hassk.) is a traditional plant from Kalimantan that is rich in flavonoid compounds that may interact with these molecular targets. This study aimed to evaluate the molecular interactions, drug-likeness, and pharmacokinetic properties of Bajakah flavonoid compounds through in silico approaches. Lipinski's rule of five and ADMET predictions indicated favorable drug-likeness and absorption profiles for most compounds, although some displayed moderate intestinal absorption and potential mutagenicity. Among the evaluated compounds, hesperetin showed the most favorable predicted binding affinity toward VEGFR-2 (binding energy -9.57 kcal/mol; predicted Ki 97.00 nM), while apigetrin demonstrated the lowest predicted binding energy toward c-MET (-9.43 kcal/mol; predicted Ki 122.94 nM). Both compounds exhibit interactions comparable to reference drugs cabozantinib and crizotinib, suggesting their potential as natural lead compounds for anticancer therapy. Further in vitro and in vivo studies are warranted to confirm their efficacy and safety.
Co-Authors Ismail, Dzava Prawinsyah Fairus Pendy, Violent Irene Shafa, Nafis Yenny Febriani Yun, Yenny Febriani